Tevogen Bio Highlights Promising Trial Data As CEO Expresses Optimism About Scientific Breakthrough In Mainstreaming Off-The-Shelf T-Cell Therapies

Benzinga · 10/15 15:38

Phase 1 Data Shows TVGN 489 Well-Tolerated With 99% Viral Elimination By Day 14 In High-Risk Patients; Persistence Of Donor-Derived CTLs Observed Through 6-Month Follow-Up; CEO Believes ExacTcell Platform Will Revolutionize Cell Therapy Across Virology, Oncology, And Neurology